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well be more informative and useful for 
the identification of other AD suscepti-
bility genes (Morar et al., 2007).
The picture that is beginning to 
emerge from our research suggests that 
the genetic architecture of AD is com-
posed of a complex mixture of prevalent 
FLG mutations and a large number of 
low-frequency mutations, which, when 
combined, have a significant influence 
on AD susceptibility.
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Common Ground?: Tetracyclines, 
Matrix Metalloproteinases, Pustular 
Dermatoses, and Loxoscelism
Lloyd E. King, Jr.1
The fear of spiders is ancient and common throughout much of the world. Skin 
ulceration and necrosis due to Loxosceles spider envenomation (“bites”) is 
among the best known sequelae of a usually accidental encounter. Therapies for 
Loxosceles envenomations either are not well documented or have adverse side 
effects that limit their use by generalists. Based on in vitro and in vivo studies 
in rabbits injected with purified or recombinant sphingomyelinase D2, Paixão-
Cavalcante et al. (2007) propose in this issue that topical tetracyclines could 
become safe, efficacious therapy for cutaneous loxoscelism.
Journal of Investigative Dermatology (2007) 127, 1284–1286. doi:10.1038/sj.jid.5700724
The tetracycline family is used to treat 
more than 30 dermatoses (Lebwohl et 
al., 2002) and may be useful in treating 
cutaneous Loxosceles envenomation. In 
perspective, prescribing tetracyclines in 
clinical practices varies from anecdotal 
reports to well-controlled, double-blind 
studies in large numbers of patients 
(Lebwohl et al., 2002). Off-label, empir-
ical therapy based on efficacious, safe 
clinical outcomes in treating benign 
and clinically severe pustular, bullous, 
and scarring dermatoses is so common 
that most dermatologists are not very 
concerned about using tetracyclines in 
this way. The mechanisms of how tetra-
cyclines generate their non-antimicro-
bial effects in acne vulgaris and other 
dermatoses are not well understood. 
The data of Paixão-Cavalcante et al., 
2007 (this issue) on Loxosceles sphin-
gomyelinase D2 (SMD2) and matrix 
metalloproteinases (MMPs) provide 
new insights into the pathophysiology 
of pustular dermatoses.
MMPs also have a broad spectrum 
of biological effects in various cutane-
ous and systemic disorders, including 
acneiform conditions with scarring, 
wound healing, carcinomas with and 
without metastases, and immuno-
logical disorders. For example, an 
MMP inhibitor, COL-3, has been 
used to treat AIDS-related Kaposi’s 
sarcoma (Cianfrocca et al., 2002). 
Understanding how the many forms 
of MMPs are regulated in normal and 
abnormal developing and differenti-
ated tissues is key to developing new 
therapeutic approaches, as implied by 
Paixão-Cavalcante et al. (2007).
What do MMPs and tetracyclines 
have to do with Loxosceles spider bites? 
The authors propose that topical tetra-
cyclines, via divalent cation chelation, 
inhibit the Loxosceles venom enzyme 
responsible for dermonecrosis, SMD2. 
This SMD2 inhibition decreased MMP2 
and MMP9 expression, increased 
in vitro cell viability, and inhibited 
or reduced skin ulceration in vivo. 
In previous studies cited by Paixão-
Cavalcante et al. (2007), the authors 
found that activated MMP(s) cleaved 
membrane-bound receptors such as 
EGFR, glycophorin, and other receptors 
involved in signal pathways including 
apoptosis and cell death (Tambourgi 
et al., 2000; Van den Berg et al., 2002). 
Such receptor proteolysis may partially 
explain why severe Loxosceles-induced 
skin ulcers are very slow to heal (Sams 
et al., 2001). The current studies do not 
address platelet activation, aggrega-
tion, and thrombosis by SMD2 only in 
the presence of acute phase reactants 
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(C-reactive protein, serum amyloid 
protein) (Gates and Rees, 1990) or spe-
cifics of the inability of luminal neutro-
phils exposed to SMD2 to transmigrate 
(Patel et al., 1994). The synergistic 
effects of other venom components are 
clearly not well understood regarding 
how Loxosceles venom both disables 
and then digests the internal structures 
of its prey for the spider to extract its 
liquid meal.
Loxosceles reclusa, aka the brown 
recluse spider (BR), receives too much 
attention as the poster child of loxo-
scelism (Swanson and Vetter, 2005). BR 
bites are often the default diagnosis for 
necrotic, ulcerating skin lesions even 
in non-indigenous areas (Swanson 
and Vetter, 2005; Norden and Phillips, 
2005). In making or dismissing a diag-
nosis of Loxosceles envenomation, too 
much weight may be given to whether 
BR spiders are indigenous to a specific 
geographical area. What is often lost in 
translation is that all BRs are Loxosceles 
but not all Loxosceles are BRs. The cul-
prit may be another Loxosceles spe-
cies, a related species, or even certain 
bacteria with active SMD (Truett and 
King, 1993). However, SMD2 is rarely 
found in nature and its presence is vir-
tually diagnostic of Loxosceles (Truett 
and King, 1993; Binford and Wells, 
2003). Riboprobes used to trace the 
evolution of Loxosceles and related 
Sicarius species from a common ances-
tor (in Africa?) show that Loxosceles are 
not the only SMD-producing spiders 
(Binford and Wells, 2003). Diagnosing 
loxoscelism strictly on lesion morphol-
ogy, spider identification, and clinical 
epidemiology while excluding other 
species and bacteria is not sufficient. 
Determining that SMD is present sero-
logically—in the bite site and in the 
suspected brown spider—would be a 
major advance. Until then, appropri-
ately designed clinical trials will suffer 
even if other identifiable causes of skin 
necrosis are excluded. If the authors’ 
studies are translated into a tetracycline 
product that effectively inactivates 
Loxosceles SMD2-induced MMPs, 
then the specific diagnosis of whether 
the pustular and/or necrotic lesion is 
due to Loxosceles may be less impor-
tant. A successful clinical outcome due 
to a specific treatment is desirable in 
pustular lesions but is not evidence of 
a definitive diagnosis without a specific 
diagnostic test.
Other agents that affect neutrophil-
induced vascular and cutaneous dam-
age, such as dapsone, corticosteroids, 
and hyperbaric oxygen chambers, 
have been tested with varying results. 
Dapsone, used clinically for more than 
50 years, is the only drug approved by 
the FDA to treat the autoimmune pus-
tular dermatosis dermatitis herpetifor-
mis, despite the fact that such therapy 
does not meet the FDA’s evidence-
based medicine criteria (Lebwohl et 
al., 2002; Cianfrocca et al., 2002). 
A standard therapy for leprosy, dap-
sone is prescribed in 31 of 213 skin 
diseases described by Lebwohl et al. 
(2002) and Cianfrocca et al. (2002). It 
is not advocated as a treatment for pre-
sumed or even non-severe loxoscelism 
without prior evaluation to identify its 
potential for adverse effects such as 
hemolysis. The diagnosis of cutane-
ous loxoscelism for a single cutaneous 
pustular or necrotic lesion is a diagno-
sis of exclusion, because other enti-
ties must be excluded by appropriate 
history and testing (Sams et al., 2001). 
Experienced dermatologists are very 
comfortable with prescribing dapsone 
to treat many other dermatoses, just 
as other specialists use antineoplas-
tic or immunosuppressive agents with 
known serious side effects even for 
non-FDA-approved indications.
It would be simplistic to allocate 
all aspects of the pathophysiology of 
Loxosceles envenomation to SMD2. 
Finding other agents to synergize 
with tetracycline is a worthy goal. 
Loxosceles SMDs, as well as other bio-
logically active venom proteins, vary 
to maximize the desired effects on the 
spider’s prey (Truett and King, 1993). 
Darwin was right: all God’s creatures 
respond to evolutionary pressures on 
their genetic and environmental adap-
tations. The challenge is to better define 
the variable responses of common 
and rare human afflictions to therapy, 
toxic agents, and creatures that have 
evolved and share the Earth with us, 
sometimes in unpleasant encounters. 
Systems biology, molecular evolution, 
and pharmacogenetics provide new 
approaches to better understanding but 
may not be much more effective than 
evaluating how old therapies can be 
put to new uses.
There is at least one fly left in the tet-
racycline ointment to treat Loxosceles 
envenomation—in this study, topical 
and not oral tetracyclines had a ben-
eficial effect. Past experience with an 
FDA-approved topical tetracycline 
showed that it was not clinically effec-
tive. To build on these results in vitro 
and in vivo in rabbits, new formulations 
and testing will be required. To improve 
therapy for cutaneous loxoscelism 
in FDA-approved trials in the United 
States, a rapid, accurate diagnostic test 
will be required. It is hoped that these 
studies will generate more interest in 
loxoscelism as an orphan disease to 
develop a rapid, accurate diagnostic 
test and a safe, efficacious Loxosceles 
antivenom. If loxoscelism is better 
defined, other orphan diseases may 
receive more attention and another 
older agent, such as tetracycline, may 
be put to new uses.
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Cross-Linking of Elafin/SKALP to 
Elastic Fibers in Photodamaged Skin: 
Too Much of a Good Thing?
Joost Schalkwijk1
Muto et al. report that UVA light induces the expression of elafin, a potent 
elastase inhibitor, in skin fibroblasts. Elafin binds to elastic fibers by transglu-
taminase-mediated cross-linking and protects against proteolytic breakdown. 
Decreased degradation could contribute to accumulation of elastotic material 
in photodamaged skin. Elastase and its locally produced inhibitors play a role in 
actinic elastosis.
Journal of Investigative Dermatology (2007) 127, 1286–1287. doi:10.1038/sj.jid.5700691
The fibrillary basophilic material 
present in the upper dermis of photo-
damaged skin is largely composed of 
elastic material. It is unclear to what 
extent this accumulation is caused by 
increased synthesis of elastin or by 
breakdown of existing and nascent 
elastic fibers, or by a relative decrease 
of collagen (Lewis et al., 2004; 
Sellheyer, 2003).
The paper by Muto et al. (2007, this 
issue) contains two interesting new 
findings. First, it shows that the serine 
protease inhibitor elafin (Wiedow et 
al., 1990), otherwise known as skin-
derived antileukoproteinase (SKALP) 
(Molhuizen et al., 1993), can be 
expressed by mesenchymal cells. This is 
a surprising finding, as it was assumed 
that elafin expression was strictly lim-
ited to epithelial cells (Pfundt et al., 
1996). The authors confirm previous 
findings that resting skin fibroblasts in 
vivo and in vitro are negative for ela-
fin, but they show that UVA irradiation 
(and not UVB) induces elafin expres-
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sion in these cells. Second, it is shown 
that elafin binds to elastic fibers in vivo 
and in vitro, thereby protecting against 
elastase-mediated breakdown. Elafin 
is a member of the trappin gene family 
(Schalkwijk et al., 1999). The proteins 
encoded by the trappin family are char-
acterized by a proteinase-inhibiting 
whey acidic protein (WAP) domain and 
a domain that contains the consensus 
GQDPVK hexapeptide motifs that are 
excellent substrates for transglutamin-
ases (Molhuizen et al., 1993). Muto et 
al. (2007) show that, in vitro, elafin can 
be cross-linked to elastic fibers, while 
retaining its proteinase-inhibiting activ-
ity. Immunohistochemical analysis of 
skin biopsies from photodamaged skin 
showed strong elafin staining associ-
ated with the elastotic material. The 
accumulation of elastase inhibitors on 
elastic fibers is not unprecedented, 
as the association of another WAP 
domain protein, secretory leukocyte 
protease inhibitor (SLPI), has been 
documented in connective tissue of 
the lung (Kramps et al., 1989) and skin 
(Wingens et al., 1998).
On the basis of their findings, Muto et 
al. (2007) speculate that elafin binding 
to elastic fibers is a protective response 
against undesirable degradative action 
of elastolytic enzymes such as neutro-
phil elastase derived from the infiltrating 
cells after UV irradiation (Hawk et al., 
1988). The authors argue that the accu-
mulation of elastotic material in photo-
damaged skin is caused by decreased 
degradation of elastic fibers rather than 
by overproduction of elastic fibers. The 
findings in this paper are novel and 
exciting. I think, however, that the data 
are open to other interpretations than 
those offered by the authors. It is indeed 
very likely that elafin expression by 
fibroblasts after UVA exposure is a pro-
tective mechanism against unwanted 
breakdown of extracellular matrix mol-
ecules. I also agree with the authors that 
the accumulation of elastotic material in 
photodamaged skin could be the conse-
quence of a protective mechanism gone 
awry. Normal turnover of collagens 
and elastin is limited, and regenera-
tion of fully matured elastic fibers after 
skin injury happens very slowly, if at all. 
Teleologically speaking, our skin has 
ample reason to protect its elastic fibers, 
